Early administration of tirofiban after urokinase-mediated intravenous thrombolysis reduces early neurological deterioration in patients with branch atheromatous disease

Bin Liu, Hong Zhang, Rong Wang, Hongdang Qu, Yifei Sun, Wanlong Zhang, Shuye Zhang, Bin Liu, Hong Zhang, Rong Wang, Hongdang Qu, Yifei Sun, Wanlong Zhang, Shuye Zhang

Abstract

Objectives: To investigate the effects of early administration of tirofiban after intravenous thrombolysis on early neurological deterioration in patients with branch atheromatous disease.

Methods: We analyzed clinical data from patients with branch atheromatous disease. We enrolled seven cases into the urokinase-only (UO) control group and 10 cases into the urokinase + tirofiban (UT) treatment group. National Institutes of Health Stroke Scale (NIHSS) scores were obtained at admission and on days 3 and 5 after admission. Modified Rankin Scale (mRS) scores were obtained 3 months after admission.

Results: Significant differences between the UO and UT groups were evident on days 3 and 5 after admission. In the UT group, there was a significant difference between NIHSS scores at admission and on day 5, while there were no significant differences in scores in the UO group. The early neurological deterioration rates were not significantly different between the two groups. However, there were significant differences in these rates at 72 and 120 hours. Both the mRS scores and the prognoses at 3 months differed between the two groups.

Conclusion: Early administration of tirofiban after urokinase-mediated intravenous thrombolysis reduces early neurological deterioration and improves the long-term prognosis of patients with branch atheromatous disease.

Keywords: Branch atheromatous disease; early neurological deterioration; intravenous thrombolysis; prognosis; tirofiban; urokinase.

References

    1. Oji S, Tomohisa D, Hara W, et al. Mean platelet volume is associated with early neurological deterioration in patients with branch atheromatous disease: involvement of platelet activation. J Stroke Cerebrovasc Dis 2018; 27: 1624–1631.
    1. Tatsumi S, Yamamoto T. An autopsied case of an apparent pontine branch atheromatous disease. Eur Neurol 2010; 63: 184–185.
    1. Arboix A, Blanco-Rojas L, Martí-Vilalta JL. Advancements in understanding the mechanisms of symptomatic lacunar ischemic stroke: translation of knowledge to prevention strategies. Expert Rev Neurother 2014; 14: 261–276.
    1. Caplan LR. Intracranial branch atheromatous disease: a neglected, understudied, and underused concept. Neurology 1989; 39: 1246–1250.
    1. Nakase T, Yamamoto Y, Takagi M, et al. The impact of diagnosing branch atheromatous disease for predicting prognosis. J Stroke Cerebrovasc Dis 2015; 24: 2423–2428.
    1. Yamamoto Y, Ohara T, Hamanaka M, et al. Characteristics of intracranial branch atheromatous disease and its association with progressive motor deficits. J Neurol Sci 2011; 304: 78–82.
    1. Nakase T, Yoshioka S, Sasaki M, et al. Clinical evaluation of lacunar infarction and branch atheromatous disease. J Stroke Cerebrovasc Dis 2013; 22: 406–412.
    1. Petrone L, Nannoni S, Del Bene A, et al. Branch atheromatous disease: a clinically meaningful, yet unproven concept. Cerebrovasc Dis 2016; 41: 87–95.
    1. Sun S, Wang Y, Wang Y, et al. Lipid and hyperglycemia factors in first-ever penetrating artery infarction, a comparison between different subtypes. Brain Behav 2017; 7: e00694.
    1. Miyamoto N, Tanaka R, Ueno Y, et al. Analysis of the usefulness of the WORSEN score for predicting the deterioration of acute ischemic stroke. J Stroke Cerebrovasc Dis 2017; 26: 2834–2839.
    1. Deguchi I, Hayashi T, Kato Y, et al. Treatment outcomes of tissue plasminogen activator infusion for branch atheromatous disease. J Stroke Cerebrovasc Dis 2013; 22: e168–e172.
    1. Del Bene A, Palumbo V, Lamassa M, et al. Progressive lacunar stroke: review of mechanisms, prognostic features, and putative treatments. Int J Stroke 2012; 7: 321–329.
    1. Yamamoto Y. [Concept, pathophysiology and treatment for branch atheromatous disease]. Rinsho Shinkeigaku 2014; 54: 289–297.
    1. Yamamoto Y, Nagakane Y, Makino M, et al. Aggressive antiplatelet treatment for acute branch atheromatous disease type infarcts: a 12-year prospective study. Int J Stroke 2014; 9: E8.
    1. Kimura T, Tucker A, Sugimura T, et al. Ultra-early combination antiplatelet therapy with cilostazol for the prevention of branch atheromatous disease: a multicenter prospective study. Cerebrovasc Dis Extra 2016; 6: 84–95.
    1. Park MG, Oh EH, Kim BK, et al. Intravenous tissue plasminogen activator in acute branch atheromatous disease: does it prevent early neurological deterioration? J Clin Neurosci 2016; 33: 194–197.
    1. Philipps J, Thomalla G, Glahn J, et al. Treatment of progressive stroke with tirofiban–experience in 35 patients. Cerebrovasc Dis 2009; 28: 435–438.
    1. Torgano G, Zecca B, Monzani V, et al. Effect of intravenous tirofiban and aspirin in reducing short-term and long-term neurologic deficit in patients with ischemic stroke: a double blind randomized trial. Cerebrovasc Dis 2010; 29: 275–281.
    1. Seitz RJ, Sukiennik J, Siebler M. Outcome after systemic thrombolysis is predicted by age and stroke severity: an open label experience with recombinant tissue plasminogen activator. Neurol Int 2012; 4: e9.
    1. Li W, Lin L, Zhang M, et al. Safety and preliminary efficacy of early tirofiban treatment after alteplase in acute ischemic stroke patients. Stroke 2016; 47: 2649–2651.
    1. Benjamin EJ, Muntner P, Alonso A, et al. Heart disease and stroke statistics-2019 update: a report from the American Heart Association. Circulation 2019; 139: e56–e528.
    1. Park K, Bae J, Park M, et al. Effectiveness of intravenous tissue plasminogen activator for early neurological deterioration and outcome in cerebral branch atheromatous disease. J Neurol Sci 2015; 357: e403.
    1. Yokote A, Hashimoto K, Bikei R, et al. Elevated release of beta-thromboglobulin and platelet factor 4 in cerebral infarction patients with branch atheromatous disease: a preliminary report. Neurol Med Chir (Tokyo) 2015; 55: 809–812.
    1. Staszewski J, Pogoda A, Data K, et al. The mean platelet volume on admission predicts unfavorable stroke outcomes in patients treated with IV thrombolysis. Clin Interv Aging 2019; 14: 493–503.
    1. Khaspekova SG, Ziuriaev IT, Iakushkin VV, et al. Mean platelet volume: interactions with platelet aggregation activity and glycoprotein IIb-IIIa and Ib expression levels. Biomed Khim 2014; 60: 94–108.
    1. Khaspekova SG, Zyuryaev IT, Yakushkin VV, et al. Relationships of glycoproteins IIb-IIIa and Ib content with mean platelet volume and their genetic polymorphisms. Blood Coagul Fibrinolysis 2014; 25: 128–134.
    1. King S, Short M, Harmon C. Glycoprotein IIb/IIIa inhibitors: the resurgence of tirofiban. Vascul Pharmacol 2016; 78: 10–16.
    1. Liu J, Shi Q, Sun Y, et al. Efficacy of tirofiban administered at different time points after intravenous thrombolytic therapy with alteplase in patients with acute ischemic stroke. J Stroke Cerebrovasc Dis 2019; 28: 1126–1132.
    1. Liao S, Deng Z, Wang Y, et al. Different mechanisms of two subtypes of perforating artery infarct in the middle cerebral artery territory: a high-resolution magnetic resonance imaging study. Front Neurol 2018; 9: 657.
    1. Sun LL, Li ZH, Tang WX, et al. High resolution magnetic resonance imaging in pathogenesis diagnosis of single lenticulostriate infarction with nonstenotic middle cerebral artery, a retrospective study. BMC Neurol 2018; 18: 51.
    1. Wu C, Sun C, Wang L, et al. Low-dose tirofiban treatment improves neurological deterioration outcome after intravenous thrombolysis. Stroke 2019; 50: 3481–3487.

Source: PubMed

Patrocinadores e Colaboradores

Condições médicas

Intervenções de drogas

3
Se inscrever